Due Diligence for Investors in Groupe Athena Inc.
We have linked the company’s press release announcing the results of GATA’s first quarter (their fiscal year ends June 30th) financial results. We also linked the company’s annual report for the fiscal year ended 6-30-15 as well as the quarterly report for the period ended 9-30-15. The company’s financials are crucial due diligence. We have also linked the Barchart.com analysis which provides all the key statistics and data for the company.
Our View: Pharmaceutical companies in India are clamoring to get their products into the American and European markets and GATA was established as a company to make that happen. They have offices both in India and the USA.
GATA has 100,000,000 common shares authorized and 47 million outstanding shares. Insiders own 83% of those shares leaving a small public float of 6.4 million shares. The metrics we found going through the GATA financials were good; they have a fiscal year ending June 30th. GATA has sales in excess of $70 million and had a net profit last fiscal year of $4.6 million. GATA HAS NO DEBT and shareholder’s equity is $26.8 million. The company has experienced consistent growth in revenue, income and shareholder equity.
GATA has a market cap of less than $7million, a share price of $.14, shareholder equity at nearly $.60 per share, EPS of $.10 per share (that’s a P/E ratio of 1.4) and sales over $70 million. We wonder why these shares trade at $.14. It is most likely because these shares don’t trade. There are 40 shareholders of record and five of those are insiders that hold 83% of the company. The public float is held by 35 shareholders and on most days recently, GATA shares don’t trade. GATA shares are worth more than they trade for and may be a candidate for a good long term investment.
GATA – Annual Report – July 20, 2015
GATA – Press Release – November 9, 2015
GATA – Quarterly report – November 9, 2015
Barchart.com – Analysis – November 9, 2015
*Feature Analyst Alert*
This week’s NASDAQ alert is the lowest priced with the most upside potential that we have covered in a long time. Another reason we like this one so much their technology is proprietary. (NASDAQ: AMDA) is in the hot biotech / biomaterial space currently holding 56 patents issued and another 37 patents pending. As if that’s not enough to get you excited, (NASDAQ: AMDA) has earnings due this week Thursday November 12th, 2015.
Link to Amedica’s Investor presentation at their website- http://investors.amedica.com/downloads.cfm
Link to Amedica’s website providing information on the two analyst’ that cover their securities Needham and JMP Securities – http://investors.amedica.com/analysts.cfm
Needham and JMP’s targets are $1 and $3/share.
Our reports/releases are a commercial advertisement and are for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. Broadstreetalerts.com has not been compensated in any form by any entity for information shared on this post.
PLEASE NOTE: Broadstreetalerts.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold Broadstreetalerts.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Broadstreetalerts.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Broadstreetalerts.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead Broadstreetalerts.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Broadstreetalerts.com is compliant with the Can Spam Act of 2003. Broadstreetalerts.com does not offer such advice or analysis, and Broadstreetalerts.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, Broadstreetalerts.com has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, Broadstreetalerts.com com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. Broadstreetalerts.com is not responsible for any claims made by the companies advertised herein, nor is Broadstreetalerts.com responsible for any other promotional firm, its program or its structure.